Furthermore, the CheckMate 227 trial demonstrated that PFS was significantly longer with first-line nivolumab plus ipilimumab (7.2 months) compared to chemotherapy (5.5 months) among NSCLC patients with a high tumor mutational burden (≥10 mutations per megabase), irrespective of PD-L1 expression levels. This evidence concerns the gene CD274 and non-small cell lung carcinoma.